文献速递心血管MRPET

帕替司兰治疗降低心脏磁共振细胞外容积提示心脏淀粉样变消退

Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression.
PubMed 文献 · JACC Cardiovasc Imaging · 2020-10-28

研究纳入16例遗传性转甲状腺素蛋白心肌淀粉样变(ATTR-CM)患者接受帕替司兰治疗,其中12例同时使用二氟尼柳,并与16例回顾性匹配患者比较。治疗12个月后,帕替司兰组细胞外容积(ECV)降低(校正组间平均差-6.2%,95%CI -9.5%至-3.0%,p=0.001),N末端B型利钠肽原浓度下降、6分钟步行距离增加,骨闪烁显像心脏摄取中位降低19.6%。心脏磁共振ECV降低为部分患者ATTR心脏淀粉样变消退提供了证据。

要点

  • 帕替司兰治疗12个月后,心脏磁共振ECV校正组间平均差为-6.2%(95%CI -9.5%至-3.0%,p=0.001),提示心脏淀粉样负荷降低。
  • 骨闪烁显像显示心脏摄取中位降低19.6%(IQR 9.8%至27.1%),可作为淀粉样负荷变化的辅助影像指标。
  • 血清TTR敲低中位86%(IQR 82%至90%),82%病例敲低>80%,提示药物生物学效应与影像变化相关。

关键影像表现/征象

  • 心脏磁共振ECV在帕替司兰治疗组较匹配组降低(校正组间平均差-6.2%,95%CI -9.5%至-3.0%,p=0.001)。
  • 骨闪烁显像显示心脏摄取中位降低19.6%(IQR 9.8%至27.1%)。

诊断标准与关键数值

  • 细胞外容积(ECV)由心脏磁共振测量,用于评估心脏淀粉样负荷。
  • 血清TTR敲低中位86%(IQR 82%至90%),82%病例敲低>80%。
  • N末端B型利钠肽原浓度校正组间平均差-1,342 ng/l(95%CI -2,364至-322,p=0.012)。

临床应用与阅片要点

  • 心脏磁共振ECV mapping可用于监测ATTR-CM患者对帕替司兰治疗的淀粉样负荷变化。
  • 骨闪烁显像心脏摄取变化可作为ATTR心脏淀粉样负荷的辅助监测指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The purpose of this study was to determine the effect of patisiran on the cardiac amyloid load as measured by cardiac magnetic resonance and extracellular volume (ECV) mapping in cases of transthyretin cardiomyopathy (ATTR-CM).

BACKGROUND: Administration of patisiran, a TTR-specific small interfering RNA (siRNA), has been shown to benefit neuropathy in patients with hereditary ATTR amyloidosis, but its effect on ATTR-CM remains uncertain.

METHODS: Patisiran was administered to 16 patients with hereditary ATTR-CM who underwent assessment protocols at the UK National Amyloidosis Centre. Twelve of those patients concomitantly received diflunisal as a "TTR-stabilizing" drug. Patients underwent serial monitoring using cardiac magnetic resonance, echocardiography, cardiac biomarkers, bone scintigraphy, and 6-min walk tests (6MWTs). Findings of amyloid types and extracellular volumes were compared with those of 16 patients who were retrospectively matched based on cardiac magnetic resonance results.

RESULTS: Patisiran was well tolerated. Median serum TTR knockdown among treated patients was 86% (interquartile range [IQR]: 82% to 90%). A total of 82% of cases showed >80% knockdown. Patisiran therapy was typically associated with a reduction in ECV (adjusted mean difference between groups: -6.2% [95% confidence interval [CI]: -9.5% to -3.0%]; p = 0.001) accompanied by a fall in N-terminal pro-B-type natriuretic peptide concentrations (adjusted mean difference between groups: -1,342 ng/l [95% CI: -2,364 to -322]; p = 0.012); an increase in 6MWT distances (adjusted mean differences between groups: 169 m [95% CI: 57 to 2,80]; p = 0.004) after 12 months of therapy; and a median reduction in cardiac uptake by bone scintigraphy of 19.6% (IQR: 9.8% to 27.1%).

CONCLUSIONS: Reductions in ECV by cardiac magnetic resonance provided evidence for ATTR cardiac amyloid regression in a proportion of patients receiving patisiran.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Fontana M, Martinez-Naharro A, Chacko L, et al. Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. JACC Cardiovasc Imaging. 2020. PMID: 33129740. doi:10.1016/j.jcmg.2020.07.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。